Available Technology

PROSTATE CANCER DETECTION THROUGH WESTERN BLOT ANALYSIS OF SEMINAL PLASMA PROSTATE-SPECIFIC ANTIGEN (PSA) SUBFORMS

Prostate-specific antigen (PSA), the glycoprotein serum biomarker used for the detection of prostate cancer (PCa), has many different molecular forms. Through studies conducted at the NIST, two internally cleaved molecular subforms of PSA (~16 kDa and ~25 kDa) haveĀ  been determ ined to be downregulated in the seminal plasma of men that have PCa. The proposed invention is a new test for the detection of PCa that utilizes western blot (WB) technology to identify and quantify these two PSA subforms from seminal plasma fluid.
Inventors: 
McJimpsey, Erica
Patent Number: 
15/411,975
Internal Laboratory Ref #: 
16-007
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin